Quantcast

Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan


Shutterstock photo

On Dec 27, we issued an updated research report on Conatus Pharmaceuticals Inc. CNAT . This San Diego-based company has no approved product in its portfolio at the moment and focuses on developing its lead pipeline candidate, emricasan.

Emricasan, a caspase inhibitor, is being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis (NASH). Conatus acquired the worldwide rights to emricasan from Pfizer PFE in July 2010. It has an exclusive option, collaboration and license agreement with Novartis NVS for the worldwide development and commercialization of emricasan.

Conatus is conducting three ongoing phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by NASH. The programs are, namely ENCORE-NF (for NASH fibrosis), ENCORE-PH (for portal hypertension) and ENCORE-LF (for liver function).

Earlier this month, Conatus announced top-line results from phase IIb ENCORE-PH study, which evaluated emricasan in patients with compensated or early decompensated NASH cirrhosis and severe portal hypertension. The study examined the capacity of emricasan to reduce hepatic venous pressure gradient (HVPG) in NASH cirrhosis patients. Although emricasan demonstrated clinically meaningful treatment effects in compensated NASH cirrhosis patients, who stand at a risk of passing to the decompensation state, it failed to meet the primary endpoint.

The ENCORE-NF assessment is investigating emricasan for potential improvements in fibrosis and steatohepatitis pertaining to patients with fibrosis caused by NASH. Top-line data from the study is expected in the first half of 2019.

The ENCORE-LF study is inspecting emricasan in patients with decompensated NASH cirrhosis. Notably, top-line results from the study will be presented in mid-2019, much earlier than the previously estimated timeline of the second half of 2019.

Notably, the NASH market holds untapped prospects. People afflicted with diabetes, high cholesterol or high triglycerides are often diagnosed with the disease, which is feared to become the fastest-growing cause for liver transplant and liver cancer. With no treatments currently available for this indication, the market opportunity for emricasan seems significant. By 2025, the worldwide market for NASH treatments is estimated to reach a value of $35 billion.

Given such an upbeat scenario, we believe that emricasan has the power to capture a large market share on approval.

Apart from emricasan, another candidate in Conatus' portfolio is IDN-7314, which is currently being evaluated in a phase II study for the treatment of primary sclerosing cholangitis (PSC), a chronic liver disease. Notably, the candidate enjoys an Orphan Drug Designation (ODD) for the indication in both the United States and across the EU.

So far this year, shares of Conatus have plummeted 72.1%, significantly wider than the  industry's decrease of 7.4%.

Zacks Rank & Other Key Pick

Conatus currently carries a Zacks Rank #2 (Buy). Another top-ranked stock in the same sector is Bovie Medical Corp. BVX , sporting a Zacks Rank #1 (Strong Buy). You can see  the complete list of today's Zacks #1 Rank stocks here .

Bovie Medical's loss per share estimates has been narrowed 21.1% for 2018 and 13.5% for 2019 in the last 60 days. The stock has skyrocketed 134.3% year to date.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Pfizer Inc. (PFE): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Bovie Medical Corporation (BVX): Free Stock Analysis Report

Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Investing , Business , Stocks
Referenced Symbols: PFE , NVS , CNAT



More from Zacks.com

Subscribe







Zacks.com
Contributor:

Zacks.com

Equity Research












Research Brokers before you trade

Want to trade FX?